• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    This invention relates to novel dibenzo[d,g][1,3,6]dioxazocine derivatives represented by the general formula I <IMAGE> (I) wherein R1 and R2 independently represent hydrogen, halogen, cyano or trifluoromethyl, Y stands for hydrogen or a group of formula <IMAGE> wherein A stands for a straight or branched chained alkylene having from 2 to 5 carbon atoms and R3 and R4 independently stand for an alkyl having from 1 to 4 carbon atoms, or R3 and R4 together with the nitrogen atom they are attached to and optionally together with a further nitrogen atom or with an additional oxygen atom may form a five- or six-membered heterocyclic ring optionally substituted with an alkyl having from 1 to 4 carbon atoms, and pharmaceutically acceptable acid addition salts thereof formed with an inorganic or organic acid. A process for the preparation of these compounds is also within the scope of this invention. The above compounds possess valuable pharmaceutical properties, for instance they are effective local anaesthetics and can be used for treating Parkinson syndrome.
    公开号:SU810080A3
    申请号:SU782644252
    申请日:1978-08-02
    公开日:1981-02-28
    发明作者:Рожа Ласло；Петец Луиза；Грашшер Каталин；Кошоцки Ибольа；Киселли Энике；Надь Йожеф
    申请人:Эдьт Дьедьсерведьесети Дьяр (Ино-Предприятие)；
    IPC主号:
    专利说明:

    one
    This invention relates to a process for the preparation of dibenzo (d, g) (1,3,6) dioxazocine derivatives of general formula (I)
    CH
    food R and R independently of one another denote hydrogen or halogen; V is 3- (dimethylamino) -propyl, 2-methyl-3- (dimethylamino) -butyl, 2- (piperidin-1-yl) -ethyl, 2- (4-methylpiperazin-1-yl) -ethyl or 2- (morpholi-1-yl) -ethyl,
    or their acid additive salts, which have an anesthetic effect and can be used in medicine.
     Known 2,6-dimethyl-N, N-diethylag inoacetanilide hydrochloride (lidocaine) of the formula
    .et
    HCl
    Mi-c-CHt-ir: -ti
    having local anesthetic action l j
    Also known 1-phenyl-1-cyclohexyl-3- (M-piperidino) -propanol-1-hydrochloride (trihexyphenidyl) formula
    CH
    cn snn v
    ten
    HC1
    each is widely used to treat parkinsonism 2.
    (-) 3- (3,4-dioxyphenyl) -L-alanine (levodone) is also used for the treatment of parkinsonism.
     The purpose of the invention is to obtain new dibenzo (d, g) (1,3,6) dioxazocine derivatives, expanding the range of compounds exhibiting physiological activity.
    The goal is to obtain compounds of the general formula (I) based on the known condensation reaction of a dihaloalkyl with a dioxy compound and an aminoalkylation reaction 4, which is enclosed in where R and have the above meanings, is reacted with dihalomethane of the general formula (ill) X 2 U p 0 J where x and x mean the same or different halogen atoms, in the medium of an aromatic hydrocarbon or aliphatic ketone or dimethyl sulfoxide or dimethylformamide, or dimethyl acetamide in the presence of an alkaline methane hydride alla or alkali metal or alkali metal carbonate at a temperature of from 80 to 160 ° C and the product obtained is aminoalkylated with a compound of the general formula (IV) y - C 1, where y has the above values, in the presence of aliphatic alcohol or dimethyl acetamide, or dimethyl sulfoxide at a temperature 40 to 140 ° C and the desired product is isolated in free form or in the form of an acid addition salt. The compounds of general formula (I) have a local anesthetic effect against Parkinson's disease. The acute toxicity of these compounds was established by oral administration to the mice of strain C F L Pi. The obtained LDy values for oral administration are given in Table. 1. Table Compound by LD .. mg / kg example
    In tab. 2 shows the local ane.c. The therapeutic effect for the proposed compounds is compared to lidocaine.
    From Table 3, it can be seen that at both concentrations studied, the duration of action of compounds of general formula (I) is much longer than the duration of action of lidocaine, which indicates an exclusively local anesthetic effect.
    The compounds of general formula (I) are also distinguished by their action against Parkinson's disease. This action is from-. It is used to suppress tremor tremorin 11,1- (butynylene) -dipyrrolidene-1 and to suppress the lethality of white mice from nicotine. These data are given in table. 4 and 5. Comparative substances are trihexyphenidyl and levodone. Based on the value of the ED-o and toxicity, a comparison was made between the proposed compounds and lidocaine. It has been shown that the ratio of the compounds of the general formula (|) is 2-4.5 of the value characteristic of lidocaine. Since in the study of local anesthetic effects, in addition to activity and toxicity, the duration of action is of great importance, the duration of the anesthetic effect of 0.25% and 0.5% solutions was also studied. The results are shown in Table. 3. Table 3 Duration Compound Concentration as in example I,% action, min 71.103 0.25; 0.5 11 13 14 15 67,161 53,260 Lidocain Table Compound BDuo, mg / kg, BD / U, following the example of oral Trihexy Table f Connection ED5-0 mg / kg /, following the example of oral | From the data table. 4 and 5 that the action of the compounds of the general formula (I) against Parkinson's disease exceeds the comparative substances. Example 1. 2DO-Dichloro-12H-dibenzo (d, d) (1,3, b) dioxazocin. To a suspension of 1.17 g (0.049 mol) of sodium hydride in 40 ml of H, H-dimethyl acetamide, a solution of,, 77 g (0.02 mol of 2.2-DIOXI-5, 5-dichloro-N-formyldifyl: mine (m.p. 180-182 C) in 40 MJJ N, M-dimethyl acetamide. The mixture is stirred for another 1 h. Then, 3.55 are added to the clear liquid in 30 minutes (0 , 02 mol) of methylene bromide. The reaction mixture is first stirred at 25 ° C for 5 hours, then for another 3 hours in a boiling water bath. Two thirds are dissolved, distilled, the residue is cooled, and poured onto 100 g of fine ice. The precipitation is filtered off, washed, dried and recaptured. -allized from CC, 3. 3., 5 (61%) of a white product is obtained with a mp of 194196 C. Example 2. 12N-dibenzo (d, g) (1,3,6) dioxazocin 1.0 g (0.044 g-at.) metallic sodium solution of BT in 5Q ml of ethanol; la, a solution of 5-g (0.0218 mol) of 2,2-dioxy-N-formyl-diphenylamine is added to this solution (mp. 152155 s ) in 50 ml of ethanol. The resulting clear solution is treated at 25 ° C with stirring 3.8 g (0.021 mol) of methyl bromide and KLTP t 5 h. After distilling off the solvent, the residue is extracted three times with 30 ml of boiling CCE, the extracts are filtered and the filtrate is evaporated . The remainder is crystalline .-, lysing out. ethanol. Obtain 1.5 g (20%) of a white product with so pl. 189191С. Found,%: with 73.36; H 5.41; N 6.44. C.aH „N0, (M 213.24). Calculated,%: C 73.22; H 5.20; N 6.57. Example 3. 3.10-Dichloro-12H-dibenzo (d, g) (1, 3.6) dioxazocine. A mixture of 6.3 g (0.021 mol) of 2,2-dioxy-5., 5-dichloro-N-formyl diphenylamine; 3.8 g (0.022 mol) of dibromomethane; 4.1 g (0.03 mol) of anhydrous potassium carbonate and 100 ml of N, N-dimethylacetam -... and heated at 100 ° C with vigorous stirring for 12 hours in a stream of nitrogen. After cooling, the mixture is poured onto ice, the precipitated product is filtered off, washed with water and dried. The product is then hydrolyzed with a mixture of 50 ml of ethanol and 10 ml of 20% aqueous sodium hydroxide under reflux for 1 hour. After cooling, the reaction mixture is neutralized with 37% HC and the product is isolated by adding 100 ml of water. It is filtered, washed with water, dried and recrystallized several times from CCl. 3.3 g (55.6%) of white product are obtained. Example 4. 2-Chloro-12H-dibenzo (d, g) (1,3,6) dioxazocin. A mixture of 6.7 g (0.025 mol) of 2,2-dioxy-5-chloro-L-formyldiphenylamine (mp. 152-157 s); 4.9 g (0.03 mol) of dibromomethane; 17.5 g (0.13 mol) of anhydrous potassium carbonate and 120 ml of M, M-dimethylacetamide are heated under nitrogen and kept at this temperature for 12 hours. After cooling, the reaction mixture is poured onto ice, the precipitated product is filtered off, washed with water and dried. The substance is then hydrolyzed by boiling in a mixture of 50 ml of ethanol and 10 ml of 20% sodium iodide, cooled, neutralized with 37% RC1 and the product is isolated by adding water. The residue is filtered and dried, then crystallized from isopropanol containing 20% water. 4.3 g (68%) are obtained
    white matter, so pl. and elementary analysis is similar to the product from example 1.
    Example 5. The substance was prepared as in Example 4 with the difference that ethanol was used instead of N, N-dimethylacetamide and the conversion was carried out at 80 ° C. Get 2-chloro-12H-dibenzo, g) (1,3, 6) dioxazocin. Yield 45%. Example 6. The substance is prepared analogously to example 4, however, isopropanol is used as solvent, the conversion is carried out at 80 ° C, and dibromomethane is used in an amount of 0.25 mol. 2-chloro-12H-dibenzo (d, d) (1,3,6) dioxazocine is obtained. Yield 45%.
    Example 7. The process is carried out analogously to example 4-, however, instead of dibromomethane, 2.55 g (0.03 mol) of dichloromethane are used. The mixture is converted for 24 hours at 40 ° C. 2-chloro-12H-dibenzo (d, g) is obtained -1, 3, b) dioxazocin. Yield 60%.
    Example 8. The process is carried out analogously to example 4, however, dimethyl sulfoxide is used as the solvent and the reaction is carried out at 100 ° C. Yield 60%.
    PRI me R 9. The process is carried out as in Example 4, however, the reaction proceeds in N, M-dimethylacetamide medium at 140 ° C. Yield 40%.
    Example 10. 2-Chloro-12H-12- {3-dimethylaminopropyl) -dibenzo (d, d) (1,3,6) dioxazocin.
    A suspension of 1.1 g (0.0045 mol) of 2-chloro-12H-dibenzo (d, d) (1,3,6) dioxazocine and 1.1 g (0.027 mol) of solid powdered caustic sodium in 20 ml of xylene — when the mixture is heated under reflux and water separator for 3 hours. A solution of 1.62 g- (0.013 mol) of 3-dimethylaminopropyl chloride in 15 ml of xylene is then added over 30 minutes. The mixture is boiled for another 12 hours, cooled, 30 ml of water are added and the organic phase is separated from the aqueous. A solution of 3.3 g (0.022 mol) of tartaric acid in 25 ml of water is added to the organic phase and the mixture is stirred for an additional 1 hour. After separation of the phases, the aqueous phase is treated with strong stirring with 6.4 ml (0.045 mol) of a 25% solution ammonia and 30 ml of gasoline. The phases are separated again, the gasoline phase is dried with anhydrous magnesium sulphate and the solvent is distilled off. After vacuum distillation of the crude product, 1.21 g (81.8%) of a white crystalline substance with a mp. 43-45 ° C, bp. 185-190 ° C at 0.4 mm Hg
    Found,%: C 65.78; H 6.66; C 10.52; N 8.40.
     N. (M 332.833) Crossed out,%: C 64.96; H 6.36; . 1 10.56; N 8.42.
    Example 11. Maleinate 2-chloro-12H-12- (3-dimethylaminopropyl) -d6eH3o (d, g) (1,3,6) dioxazocine.
    1.56 g (0.0047 mol) of 2-chloro-12H-12- (3-dimethylaminopropyl) -dibenzo (d, g) (1,3,6) dioxazocine is dissolved in 20 ml of absolute ether and to the solution with stirring 0.07 g (0.00 mol) maleic acid in 40 ml of absolute ether is added. The mixture is stirred for 1 h, then the precipitate is filtered off, washed with absolute ether and recrystallized from isopropanol. 1.51 g (71.7%) of a snow-white product are obtained with a mp. 132-13bs. /.
    Found,%: C 59, 26; H 5, 65; Ce 7,89; N 6.17.
    , (M 448,915)
    Calculated,%: C 58.86; N 5.61; Cr 7.9; N 6.24.
    Example 12. 2-Chloro-12H- (2-pperidiioethyl) -dibenzo (d-, g) (1,3,6) dioxazocin.
    A suspension of 2.8 g (0.01113 mol) of 2-chloro-12H-dibenzo (d, g) (1,3,6) -dioxazazin and 3.1 g (0.078 mol) of solid powdered caustic sodium 70 ml of xylene bale t in a flask under reflux and water separator for 3 hours. Then, 5 g (0.034 mol) of N- (2-chloroethyl) -piperidine in 30 ml of xylene is added to the mixture over 30 minutes and boiled for another 12 hours. Further processing lead analogously to the example. The crude product crystallizes willows of isopropanol. 3.44 g of an 85.6% white product are obtained with a mp. 87-89C.
    Found,%: C 66-, 15; H 7.4; C, 9.98; N 7.9.
    Cjo. (M 358,877)
    calculated,%: C, 66.94; H 6.46; Ct 9.88; N 7.81.
    Example 13. 2-ChLOR-12H-12- (2-piperidinoethyl) -dibenzo (d, g) (1,3,6) dioxazocine hydrochloride.
    A solution of 3.44 g (0.0096 mol) of 2-HLOR-12H-12- (2-piperidinoethyl) -dibenzo (d, 9) (1,3,6) dioxazocine in 40 ml of absolute ether is cooled d and added with stirring 15% hydrochloric ether to pH -2-3. The precipitated white crystals are filtered and suspended by washing in ether. After recrystallization from isopropanol, 3.17 g (83.6%) of white hydrochloride with m.p. 201-2-03 ° C.
    Ngdydeno.%: C 59.94; H 5.69; Ct 17.97; N 7.17; CI- 8.95.
    C20 "24 .0 2 (M 395,342)
    Calculated,%: C 60.76; H 6.12; CE 17.94; N 7.09; Ct - 8.97.
    Example 14. 2-Chloro-12H-12H-- hydrochloride (2-methyl-3-dimethylaminopropyl) -dibenzo (d, g) (1,3,6) dioxazocine.
    权利要求:
    Claims (4)
    [1]
    A suspension of 1.44 g (0.0058 mol) of 2-chloro-12H-dibenzo (d, d) (1,3,6) dioxazocin and 1.4 g (0.036 mol) of powdered sodium hydroxide in 30 xylene is boiled in a flask under reflux and water separator for 3 hours. Then, 2.46 g (0.0174 mol) of 2-methyl-3-dimethylaminopropyl chloride in 15 xylene is added over 30 minutes. The mixture was boiled for another 12 hours and was treated analogously to Example 2. 1.87 were obtained. g (90.6%) of the free base as a white substance with m.p. 72-75 C. This base is transferred to the hydrochloride in the same manner as Example 5. It is crystallized from isopropano. 1.63 g (73.2%) of hydrochloride are obtained with a mp. 184-18b with. Found,%: C 59.66; H 6.38; Ct 18.57; N 7.35; SI 9.23. q, .0i (M 383.931) Calculated,%: C 59.5-3; H 6.31; C 18.50; N 7.31; C1 9.25. : EXAMPLE 15 2-HLOR-12H-12- (2-M-methylpiperazine) ethyl-dibenzo (d, g) (1, .3.6) dioxazocyto dichlorohydrate (1, .3.6) dioxazocyte Suspension 1.24 g (0.005 mol ) 2-HLOR-12H-dibenzo (d, g) (1,3,6) dioxazine and 1.2 g (0.03 mol) of porous caustic sodium in 20 ml of xylene are boiled for 3 hours while stirring with a reflux condenser and a pre-sampler. A solution of 2.44 g (0.015 mol of 1-methyl-4- (2-chloroethyl) -gp-perazine in 20 ml of xylene) is then added over 30 M and the mixture is boiled for another 12 hours. After treatment as in Example 5, hydrochloride is formed After its crystallization from methano, 1.61 g (72.2%) of pure white dihydrochloride are obtained with mp 2 O1-203 C. Found: C 52.55; H 5.80; Cr 23.5; N 9 , 35. Z (M 446.823) Calculated,%: C 53.76; H 5.87; Cr 23.81; N 9.41. Example 16. Maleinate 2-chl-12H-12- (2-morpholinoethyl) - diben3o (d, g) (1,3,6) dioxazocine. Suspension 0.99 g (0.004 mol) 2-chlorop-12H-dibonzo (d, d) (1,3.6) dioxazocine and 0.96 g ( 0.02 mol) powdered sodium hydroxide in 20 ml of xylene boil 3 hours. A solution of 1.79 g (0.012 mol of N-2-chloroethidmorpholine in 12 ml of xylene is added over 30 minutes and the mixture is boiled for 12 hours. After processing the mixture in analogy to Example 2, 1 g of a crude base. From which maleate is obtained analogously to Example 3. After crystallization from isopropanol, 1.04 g (54.8%) of snow-white mapeinate with m.p. 151-152С. Found,%: C 58.19; H 5.45; CE 7.49; N 5.87. CjaHogClN O- (M 476.926) Calculated; %: C 57.92; H 5.28; Cr 7.43; N 5.88. Example 17. Malein 2.10 dichloro-12H-12- (3H-dimethylaminopropyl) -dibenzo (d, g) (1,3,6) dioxazocine. A mixture of 11.3 g (0.04 mol) of 2,10-dichlor-12H-dibenzo (d, d) (1,3,6) dioxazocin, 9.6 g (0.24 mol) of sodium hydroxide and 450 ml of xylene boil in an instrument equipped with a water separator with vigorous stirring for 2 hours. Then a solution of 19.4 g (0.16 mol) of 3-dimethylaminopropyl chloride in 250.ML xylene and 20 g of potassium iodide is added to the mixture and boiled for another 12 hours The mixture is then worked up as in Example 2. 14 g of a crude non-crystallizing base are obtained. To a solution of 14 g (0.0382 mol) of a crude base in 150 ml of absolute ether, a solution of 4.4 g (0.382 mol) of maleic BOJi acid in 320 ml of absolute ether is added with stirring. The mixture is stirred for 1 h, the precipitated product is filtered, washed with absolute ether and crystallized from acetonitrile. 13.4 g (69.5%) of white maleate are obtained with a mp. 190-193 C. Found,%: C 54.82; H 4.96; Ct 14,54; N 5.7. . (M 483.364) Calculated,%: C 54.67; H 5.01; CE 14.67; N 5.80. Example 18. The substance was prepared as in Example 10, however, dimethyl sulfoxide was used as a solvent instead of xylene, and the conversion was carried out at 100-110 ° C. Get 2-HLOR-12N-12- (3-dimethylaminopropyl) -dibenzo (d, g) (1,3,6) dioxazocin. The output of 80.5%. PRI me R 19. The substance is prepared as in Example 18, but sodium hydride is used instead of sodium hydroxide. 2.-chloro-12H-12- (3-dimethylaminopropyl) -dibenzo (d, g) (1,3,6) dioxazocine is obtained. 75% yield. Example 20. The process is carried out taxically to Example 12 with the difference that methyl ethyl ketone is used as the solvent and the transformation is carried out at. 2-chloro-12H12- (2-piperidineethyl) -dibenzo (d, g) (1,3,6) dioxazocin is obtained. Yield 82%. Example 21. The process is carried out taxically to Example 10, however dimegylformamide is used as a solvent and the conversion is carried out at 50-155 ° C. Yield 86%. Example 22. The substance will be obtained analogously to example 10, however, as a solvent instead of xylene, N, H-dimethylacetamide is used and reaction is carried out at. Get-chloro-12H-12- (3-dimethylaminopropyl) dibenzo (d, g) (1,3,6) dioxazocin. Output 65%. DETAILED DESCRIPTION OF THE INVENTION Method for producing 6eH3o (d, g) (1,3,6) dioxazocine derivatives of the formula I O-CHi jj where R and R 2 independently of one another denote hydrogen or halogen, y is 3m {dimethylamino) -propi 2-methyl- 3- (dimethylamino) butyl - {piperidin-1-yl) -ethyl, 2- (4-m piperazin-1-yl) -ethyl or 2- (mol-1-yl) -ethyl, or their acid additive Sol characterized in that the compounds of the general formula II and R have the above </ BR> where R. The reaction is reacted with dihalomethane of the general formula ItI g, t where x and Xj. means the same or different halogen atoms, in the medium of an aromatic hydrocarbon, or an aliphatic ketone, or dimethyl sulfoxide,. or dimethylformamide or dimethylacetamide in the presence of an alkali metal hydride or alkali metal or alkali metal carbonate at a temperature of 80 to and the resulting product is aminoalkylated by a compound of general formula IV,. . y - CH where y has the above values, in the presence of an aliphatic alcohol or dimethylacetamide or dimethyl sulfoxide at a temperature of from 40 to 14 ° C and the target product is isolated in free form or in the form of an acid addition salt. Sources of information taken into account with the expert examination 1. Mashkovsky M, D. Medicinal products, M., Medicine, t.1, p.295.
    [2]
    2. In the same place, p.146.
    [3]
    3. Tam.zhe, p.153.
    [4]
    4. Weigand-Hilgetag. Methods of ex. Experiment and organic chemistry. M., Himi, 1968, p. 329.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU852174A3|1981-07-30|Method of preparing cycloalkyltriazoles or theirs alts
    DK200300345U3|2004-03-12|Amlodipine maleate and pharmaceutical composition containing amlodipine maleate
    EP1511739B1|2008-04-30|Polymorphs of valsartan
    EP0434561B1|1995-10-18|1-Naphthyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them
    FR2664592A1|1992-01-17|NOVEL DERIVATIVES OF PIPERIDINE, TETRAHYDROPYRIDINE AND PYRROLIDINE, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
    FR2518993A1|1983-07-01|2- |) - 1-PIPERAZINYL) PYRIMIDINES, THEIR PREPARATION AND THEIR PHARMACOLOGICAL APPLICATION
    EP0487408A1|1992-05-27|Oxazolopyridine derivatives, process for their preparation and pharmaceutical compositions comprising the same
    JPH08506354A|1996-07-09|Process for producing 5- [2- | -piperazin-1-yl) ethyl-6-chloro-1,3-dihydro-indol-2-one and intermediate for the production
    JP2502343B2|1996-05-29|A pharmaceutically active substituted benzamide
    SU810080A3|1981-02-28|Method of preparing |dioxazocin derivatives or their acid-additive salts
    JP2014012682A|2014-01-23|Method for synthesizing heterocyclic compound
    US3141019A|1964-07-14|Chaohj
    KR920005827B1|1992-07-20|Benzothiadiazepine derivatives
    JP3135170B2|2001-02-13|Aminomethyl-substituted 2,3-dihydropyrano [2,3-b] pyridines
    KR910003711B1|1991-06-08|Process for preparing 2-|-3-isobutoxy-n-substituted phenyl-n-benzylpropylamines
    SU784763A3|1980-11-30|Method of preparing 6-methoxy-2-acetylnaphthyloxime derivatives of their hydrochlorides
    FR2663929A1|1992-01-03|NOVEL OXAZOLO PYRIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
    EP0230020A2|1987-07-29|1,2,3,4,4a,9b-Hexahydro-4a-aminoalkyldibenzofurans, a process for their preparation and their use as medicaments
    GB2162843A|1986-02-12|Piperazine derivatives
    JP2967231B2|1999-10-25|1,4-thiazine derivatives
    KR880001715B1|1988-09-08|Process for preparing 1-furyl-3,4-dihydro-isoquinolines
    US4058616A|1977-11-15|2-[N-|-amino]-4-phenyl-2-imidazolines and salts thereof
    US4703055A|1987-10-27|Benzamides and therapeutic use thereof
    SU1033001A3|1983-07-30|Process for preparing derivatives of aminoisoquinoline or their acid addition salts
    FR2552762A1|1985-04-05|NOVEL PIPERAZINIC AND HOMOPIPERAZINIC AMIDES DERIVED FROM CINNAMIC ACID 3,4-DIOXYMETHYLENE ACID, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION
    同族专利:
    公开号 | 公开日
    US4229350A|1980-10-21|
    ATA515578A|1980-12-15|
    CH635834A5|1983-04-29|
    FI782340A|1979-02-03|
    IT1097994B|1985-08-31|
    PL111253B1|1980-08-30|
    NL187574C|1991-11-18|
    DK340478A|1979-02-03|
    YU40718B|1986-04-30|
    HU174126B|1979-11-28|
    FI63566C|1983-07-11|
    GB2001980A|1979-02-14|
    DE2833892C2|1986-08-07|
    AT363091B|1981-07-10|
    IT7826351D0|1978-08-01|
    AU3839678A|1980-01-31|
    CS207639B2|1981-08-31|
    DE2833892A1|1979-02-22|
    YU182178A|1983-02-28|
    SE441828B|1985-11-11|
    SE7808234L|1979-02-03|
    NL187574B|1991-06-17|
    DK149889C|1987-04-27|
    FR2399417B1|1981-02-13|
    FI63566B|1983-03-31|
    DK149889B|1986-10-20|
    NL7808124A|1979-02-06|
    GB2001980B|1982-01-13|
    US4208410A|1980-06-17|
    AU517160B2|1981-07-09|
    PL208762A1|1979-06-04|
    FR2399417A1|1979-03-02|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3591604A|1968-10-01|1971-07-06|Squibb & Sons Inc|Derivatives of dibenzoxazocine and dibenzthiazocine|HU195491B|1985-12-20|1988-05-30|Egyt Gyogyszervegyeszeti Gyar|Process for production of optically active 2-chlor-12-/3-/dimethil-amin/-2-methil-prophil/-12h-dibenzol /d,g/ /1,3,6/-diaxazocine and medical compositions containing such compounds|
    HU198194B|1986-12-30|1989-08-28|Egyt Gyogyszervegyeszeti Gyar|Process for production of new derivatives of dioxazocin and medical compositions containing them|
    HU201318B|1987-12-31|1990-10-28|Egyt Gyogyszervegyeszeti Gyar|Process for producing dioxazoline derivatives and pharmaceutical compositions comprising same|
    US4966967A|1989-09-15|1990-10-30|Berlex Laboratories, Inc.|3,4,5,6-tetrahydro-2H-1,7,4-benzodioxazonines as cardiovascular agents|
    DE69622415T2|1995-09-19|2003-03-06|Novo Nordisk As|12H-Dibenzo [d, g] [1,3] dioxocin derivatives|
    WO1998015548A1|1996-10-04|1998-04-16|Novo Nordisk A/S|1,4-disubstituted piperazines|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    HU77EE2515A|HU174126B|1977-08-02|1977-08-02|Process for producing new dibenzo-square bracket-d,g-square bracket closed-square bracket-1,3,6-square bracket closed--dioxazocine-derivatives|
    [返回顶部]